|
|
|
|
|
What We
Do with
Emerging
SARS-CoV-2
Variants |
Multiple SARS-CoV-2 variants are circulating globally. Several new variants emerged in the fall of 2020, most notably: |
|
|
In the United Kingdom (UK), a new variant of SARS-CoV-2 (known as 20I/501Y.V1, VOC 202012/01, or B.1.1.7) emerged with an unusually large number of mutations. |
|
|
In South Africa, variant known as 20H/501Y.V2 or B.1.351 emerged independently of B.1.1.7. View More | |
|
Creative Diagnostics has produced a collection of recombinant antigens to evaluate the efficacy of the antibodies and vaccination for these variants. | |
|
|
|
|
|
Our team has been keeping close attention to these?new variants and?is working diligently to develop a serial of Lentiviral SARS-CoV-2 Mutation Pseudovirus. | |
|
|
Lentiviral SARS-CoV-2 Mutation Pseudovirus | |
|
|
|
CD anti-nucleoprotein antibodies are expected to detect both UK and South African variants of SARS-CoV-2. | |
|
|
SARS-CoV-2 Nucleoprotein Antibody Pairs for Rapid COVID-19 Antigen Assays | |
|
|
|
Best pairs in lateral flow: If you are developing a lateral flow-based test, we recommend starting with these two capture-detection pairs: CABT-MMB1-CABT-RMJ1, and CABT-MMB1-CABT-MMB2. | |
|
|
New MAbs Available |
|
We are pleased to let you know that we now have the first anti-nucleoprotein antibody (CABT-MMT2) that can not react with the B.1.1.7 variant strain but react with other COVD-19 viral strains. |
|
This antibody can be used for COVID-19 antigen lateral flow testing in differentiating Variant B.1.1.7 and other viral strains. | |
|
We remain focused on our mission to serve life scientists to achieve their mission, faster. We know that many scientists are still diligently pursuing their research, and we'll continue to support our customers and partners worldwide. | |
|
|
|
|
